RxDoctor Payments Data

Vincent Valencia, MD

Family Medicine · Adel, GANPI 1134359243

Payments from drug & device makers

$769in general payments, 2019–2025

Across 43 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$273
  • Dexcom, Inc.$111
  • Supernus Pharmaceuticals, Inc.$90
  • GSK$71
  • Sunovion Pharmaceuticals Inc.$41
  • Phathom Pharmaceuticals, Inc.$26
  • plus $158 from 9 others

What the payments were for

  • Food & beverage$769100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$769 in reported general payments places this provider in the 55th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$7,166
Medicare patients
50
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide105$137,247
EliquisApixaban170$132,441
OzempicSemaglutide95$99,525
TrulicityDulaglutide62$76,570
JardianceEmpagliflozin52$70,154
JanuviaSitagliptin Phosphate45$51,006
LinzessLinaclotide40$29,054
XareltoRivaroxaban21$21,335
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,600
Lantus SolostarInsulin Glargine,hum.Rec.Anlog122$18,215
Spiriva HandihalerTiotropium Bromide19$18,081
Breo ElliptaFluticasone/Vilanterol21$13,250
Spiriva RespimatTiotropium Bromide19$12,711
SymbicortBudesonide/Formoterol Fumarate41$12,561
TradjentaLinagliptin12$8,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$25$213,816167 claims
PfizerEliquis$11$132,441170 claims
Novo NordiskOzempic$273$99,52595 claims
GSKTrelegy Ellipta, Breo Ellipta$71$32,85041 claims
Johnson & JohnsonXarelto$15$21,33521 claims
Astellas Pharma US IncMyrbetriq$18$6,34117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Adel

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →